Published in Semin Liver Dis on February 22, 2011
Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A (2014) 1.71
Development of the bile ducts: essentials for the clinical hepatologist. J Hepatol (2012) 1.55
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol (2013) 1.04
Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol (2012) 1.03
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol (2014) 1.01
The portal fibroblast: not just a poor man's stellate cell. Gastroenterology (2014) 0.93
Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. Stem Cell Res Ther (2014) 0.91
Vascular biology of the biliary epithelium. J Gastroenterol Hepatol (2013) 0.91
Keratin 19 epithelial patterns in cirrhotic stroma parallel hepatocarcinogenesis. Am J Pathol (2011) 0.84
The crucial role of cholangiocytes in cholangiopathies. Gut Liver (2012) 0.84
Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury. Gut (2014) 0.81
Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol (2014) 0.81
Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats. PLoS One (2012) 0.81
Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology (2016) 0.81
Neural cell adhesion molecule and polysialic acid in ductular reaction: the puzzle is far from completed, but the picture is becoming more clear. Hepatology (2014) 0.79
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? J Clin Med (2015) 0.79
Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype. Stem Cells Int (2016) 0.78
Pericytes, microvasular dysfunction, and chronic rejection. Transplantation (2015) 0.77
Portal Fibroblasts in Biliary Fibrosis. Curr Pathobiol Rep (2014) 0.76
In situ characterization of intrahepatic non-parenchymal cells in PSC reveals phenotypic patterns associated with disease severity. PLoS One (2014) 0.75
Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. Int J Mol Sci (2017) 0.75
Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. Transl Gastrointest Cancer (2013) 0.75
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol (2004) 24.63
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Smad transcription factors. Genes Dev (2005) 13.43
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet (1997) 6.66
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med (1997) 6.39
Identification and characterization of a fibroblast marker: FSP1. J Cell Biol (1995) 6.33
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Notch signaling: control of cell communication and cell fate. Development (2004) 5.95
Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet (1997) 5.58
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell (1986) 4.10
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Regulation of notch signaling activity. Curr Biol (2004) 3.88
Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity (2007) 3.61
NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet (2006) 3.55
Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol (2002) 3.52
Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol (2006) 3.42
Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol (1991) 3.41
Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol (2004) 3.34
WNT/beta-catenin signaling in liver health and disease. Hepatology (2007) 3.26
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 3.20
Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell (1993) 3.17
Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology (2010) 3.10
Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol (1998) 3.09
Notch signaling controls liver development by regulating biliary differentiation. Development (2009) 2.93
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A (1996) 2.93
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Notch signaling in stem cell systems. Stem Cells (2006) 2.82
Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A (2006) 2.75
Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol (2005) 2.72
TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 2.68
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol (2002) 2.65
Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol (2007) 2.64
Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol (1990) 2.64
Mammary stem cells and breast cancer--role of Notch signalling. Stem Cell Rev (2007) 2.62
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun (2006) 2.52
The bone marrow functionally contributes to liver fibrosis. Gastroenterology (2006) 2.52
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest (1989) 2.46
Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol (2008) 2.42
The role of CXC chemokines in pulmonary fibrosis. J Clin Invest (2007) 2.41
Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest (1989) 2.41
Notch signaling and inherited disease syndromes. Hum Mol Genet (2003) 2.40
Signaling pathways governing stem-cell fate. Blood (2007) 2.38
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood (2007) 2.37
Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis (2001) 2.35
Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut (2007) 2.35
Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology (2009) 2.33
Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep (2010) 2.32
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Biology of vascular endothelial growth factors. FEBS Lett (2006) 2.26
The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut (2008) 2.26
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest (2007) 2.03
Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors. Genes Dev (2005) 2.02
Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol (1998) 2.01
Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2007) 1.99
Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology (2010) 1.97
Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One (2010) 1.94
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol (2005) 1.93
A proximal activator of transcription in epithelial-mesenchymal transition. J Clin Invest (2007) 1.93
Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities. Mayo Clin Proc (1998) 1.92
Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology (2006) 1.86
Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy. Development (2004) 1.85
Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine-rich protein. Cell Growth Differ (1991) 1.80
Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology (2007) 1.80
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. J Cell Sci (2004) 1.78
Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology (2003) 1.78
Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol (2006) 1.76
Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol (2001) 1.74
Gastrointestinal stem cells in development and cancer. J Pathol (2009) 1.73
Characterization of renal interstitial fibroblast-specific protein 1/S100A4-positive cells in healthy and inflamed rodent kidneys. Histochem Cell Biol (2005) 1.69
Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology (2009) 1.69
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med (1998) 1.66
Noncanonical Wnt signaling and neural polarity. Annu Rev Neurosci (2006) 1.63
Pathophysiology of cholangiopathies. J Clin Gastroenterol (2005) 1.63
Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol (2006) 1.61
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut (2003) 1.60
The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest (2003) 1.57
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology (2008) 1.56
The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver development, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol (2008) 1.56
Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology (1996) 1.55
Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol (1991) 1.55
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology (2002) 1.79
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology (2013) 1.65
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology (2007) 1.59
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
"The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. J Hepatol (2011) 1.42
Emerging roles of Notch signaling in liver disease. Hepatology (2014) 1.39
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol (2008) 1.12
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (2012) 1.09
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology (2011) 1.07
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol (2013) 1.04
Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology (2008) 1.03
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol (2010) 1.02
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl (2002) 0.99
Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology (2012) 0.98
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology (2011) 0.96
Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. Clin Res Hepatol Gastroenterol (2013) 0.92
Vascular biology of the biliary epithelium. J Gastroenterol Hepatol (2013) 0.91
Defective regulation of cholangiocyte Cl-/HCO3(-) and Na+/H+ exchanger activities in primary biliary cirrhosis. Hepatology (2002) 0.91
Protein kinase A-dependent pSer(675) -β-catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis. Hepatology (2013) 0.88
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. Dig Liver Dis (2010) 0.87
Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology (2005) 0.86
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl (2010) 0.85
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Dig Dis (2015) 0.83
Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int (2006) 0.83
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol (2012) 0.83
Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Oncol Rep (2013) 0.82
Extended right split liver graft for primary transplantation in children and adults. Transpl Int (2006) 0.81
Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol (2007) 0.81
Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats. Virchows Arch (2004) 0.80
Systemic therapy in hepatocellular carcinoma. Clin Liver Dis (2011) 0.78
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma: the egg of columbus or another illusion? Hepatology (2013) 0.77
Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer (2008) 0.76
Healthcare costs associated with hepatocellular carcinoma and the value of care. Hepatology (2013) 0.75
Hepatic venous pressure gradient (HVPG), serum sodium (SNa), and model of end-stage liver disease score (MELD): prognostic significance and correlations. J Clin Gastroenterol (2007) 0.75
Toward a rational management of very early hepatocellular carcinoma. Hepatology (2013) 0.75
Type I autoimmune hepatitis presenting with acute liver failure in the setting of wild mushroom ingestion. J Clin Gastroenterol (2008) 0.75
Prognostic prediction in hepatocellular carcinoma: from art to science. J Clin Gastroenterol (2008) 0.75
EASL recognition awardee 2013: Professor Jesus Prieto. J Hepatol (2013) 0.75
[Antiplatelet drugs and gastrointestinal bleeding: numquam periclum sine periclo vincitur]. Ital Heart J Suppl (2005) 0.75
Isolated idiopathic bile ductular hyperplasia in patients with persistently abnormal liver function tests. J Hepatol (2004) 0.75